Coverage
-
March 29, 2017
The Rosen Law Firm did not engage in "abusive litigation" when filing a shareholder suit that alleged Cellceutix Corp. had hyped two of its drugs to inflate stock prices, a New York federal judge ruled Wednesday, refusing to sanction the firm for soliciting investors just hours after a report attacked Cellceutix's business.
2 other articles on this case.
View all »